How to cite: Link RE. “Salvage Partial and Radical Nephrectomy: Principles and Strategies.” September 19, 2025. Accessed Feb 2026. https://grandroundsinurology.com/salvage-partial-and-radical-nephrectomy-principles-and-strategies/

Summary

Richard E. Link, MD, PhD, Carlton-Smith Endowed Chair in Urologic Education, Baylor College of Medicine, Houston, Texas, presents a practical framework for performing salvage partial and radical nephrectomy in patients with recurrent or residual renal cell carcinoma. He explains that effective salvage surgery depends on careful patient selection and a clear understanding of tumor biology, prior treatment, and anatomical context. When appropriately selected, minimally invasive robotic techniques can be performed safely and reproducibly.

Dr. Link emphasizes that oncologic factors are the primary drivers of surgical decision-making. Surgeons must determine whether salvage nephron-sparing surgery is appropriate based on patient characteristics, such as renal function, comorbidities, and performance status, and tumor factors, including pathology, growth kinetics, and recurrence location. He distinguishes scenarios that favor nephron preservation, such as small, slow-growing, superficial recurrences, from those requiring salvage radical nephrectomy, including aggressive histology, early recurrence, or indistinct margins.

He reviews technical considerations that follow once oncologic criteria are satisfied. Longer intervals between surgeries generally improve the feasibility of nephron-sparing approaches, with vascular control and hilar dissection often less challenging than expected. Dr. Link outlines how the kidney can be approached via transperitoneal or retroperitoneal compartments, emphasizing the efficiency and lower morbidity associated with regionalized retroperitoneal surgery, particularly in the salvage setting.

Using detailed case examples, Dr. Link illustrates surgical planning for different anatomic and pathologic scenarios, including posterior and anterior recurrences, locally advanced disease, and cases following prior ablation or partial nephrectomy. He emphasizes the importance of flexibility in selecting surgical access based on a patient’s prior operative history and imaging findings. He argues that while these operations are complex, most can be safely accomplished with minimally invasive robotic techniques when guided by oncologic principles and individualized strategy.

 

About The 29th Annual Innovations in Urologic Practice:

Presented by co-chairs Mohit Khera, MD, MBA, MPH, and Michael Coburn, MD, FACS, the Innovations in Urologic Practice conference provides a detailed review and commentary on multiple genitourinary and urologic diseases. Among the featured oncological topics are bladder cancer and immunotherapies, as well as upper tract cancer management, prostate cancer, including state-of-the-art imaging, focal therapy, and MRI. Experts also discuss new tools and techniques for nephrectomy and treating advanced renal cell carcinoma. In terms of general urological approaches, the conference also includes pelvic reconstruction and trauma, men’s health topics like male infertility and sexual dysfunction, and ways to diagnose and treat infections in the urology patient.

For further educational activities from this conference, visit our collection page.

ABOUT THE AUTHOR

+ posts

Richard E. Link, MD, PhD, is a professor and board-certified and fellowship-trained urologist specializing in the treatment of urologic disease affecting the kidney, ureter, adrenal gland and prostate. Dr. Link holds the Carlton-Smith Endowed Chair in urologic education at the Baylor College of Medicine (BCM) in Houston, Texas and directs the BCM division of endourology and minimally invasive surgery. He serves as director of living donor procurement for several major kidney transplant programs in Houston, including Baylor St. Luke’s Medical Center, Texas Children’s Hospital, and the Houston Methodist Hospital. Dr. Link focuses on the use of laparoscopic, robotic-assisted, percutaneous, and endoscopic techniques to treat kidney and prostate tumors, benign prostatic hypertrophy, renal and ureteral obstruction, and urinary tract stones and has been an early pioneer in the development of laparoendoscopic single-site donor nephrectomy.

Dr. Link earned both his MD and PhD in molecular and cellular physiology at Stanford University in California and completed an internship and residency at BCM before completing a fellowship at The Johns Hopkins University School of Medicine in Baltimore, Maryland. Dr. Link also has a strong interest in applying single site robotic technology using the da Vinci SP platform to retroperitoneal and transvesical urologic surgery. He has published numerous papers and earned many awards, including the Fulbright and Jaworski LLP Faculty Excellence Award for Teaching and Evaluation at BCM.